Search results
Showing 51 to 100 of 109 results for chronic heart failure in adults: management
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Palliative care for adults: strong opioids for pain relief (CG140)
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with a beta-blocker licensed for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM173
This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over with heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM238
This indicator covers the percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional capacity (using the New York Heart Association classification) and a review of medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM174
This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies.
This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator covers the percentage of patients registered at the practice aged 65 years and over who have been diagnosed with 1 or more of the following conditions: coronary heart disease, heart failure, hypertension, diabetes, CKD, PAD, or stroke/TIA who have had a pulse rhythm assessment in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM146
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
Biographies and registered interests for members of the Technology Appraisal Committee A
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
Optimising Medication in patients with Chronic Heart Failure
focused on the management of patients with heart failure (HF) in primary care. Using a virtual clinic model,...
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
Delivering Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) in Wirral
patients with chronic heart failure. Cardiovascular rehabilitation is indicated as an effective treatment...
This quality standard covers prevention of falls and assessment after a fall in older people (aged 65 and over) who are living in the community or staying in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Identifying people at risk of falling
- Quality statement 2: Multifactorial risk assessment for older people at risk of falling
- Quality statement 3: Multifactorial intervention
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
Reducing inappropriate use of NT pro BNP: A Quality Improvement project
diagnostic pathway for suspected heart failure and is outlined in the NICE Chronic Heart...
Evidence-based recommendations on percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure in adults. This involves putting a small electronic pressure sensor into the pulmonary artery to measure blood pressure.
View recommendations for IPG711Show all sections
database Organisation: Kent Surrey and Sussex Heart Failure Collaborative Published date: June 2019
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .
NICE has developed a medtech innovation briefing (MIB) on TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure .
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
COVID-19 ready rehabilitation for heart failure: REACH-HF can deliver
(Rehabilitation EnAblement in CHronic Heart Failure) is a facilitated evidence based cardiac rehabilitation...
This guideline covers the diagnosis and management of menopause, including in women who have premature ovarian insufficiency. The guideline aims to improve the consistency of support and information provided to women in menopause.
This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.
View quality statements for QS167Show all sections
Sections for QS167
- Quality statements
- Quality statement 1: Designing health and wellbeing programmes
- Quality statement 2: Peer and lay roles
- Quality statement 3: Referring people at high risk of type 2 diabetes
- Quality statement 4: Cardiac rehabilitation
- Quality statement 5: Support for people with mental health problems
- Quality statement 6: Physical health checks for people with serious mental illness
- Update information
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
Cardiac contractility modulation device implantation for heart failure (IPG655)
Evidence-based recommendations on cardiac contractility modulation device implantation for heart failure in adults. This involves placing a device under the skin of the chest, which delivers electrical pulses to make the heart contract more strongly.
View recommendations for IPG655Show all sections
This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
diagnosing heart failure:- What are the optimal NT-proBNP thresholds for diagnosing heart failure...
Alcohol-use disorders: diagnosis and management of physical complications (CG100)
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
peptide threshold for diagnosing heart failure:- What is the optimal NT-proBNP threshold for the diagnosis of...
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
imaging techniques for diagnosing heart failure:- What is the optimal imaging technique for the diagnosis of...
non-sudden death in heart failure:- What is the most accurate prognostic risk tool in predicting 1-year mortality from...
fluid overload in people with advanced heart failure in the community:- In people with advanced heart...
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
This guideline has been updated and replaced by NICE guideline CG108.
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .